![Albert Seymour](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Albert Seymour
Directeur Général chez Seamless Therapeutics
Fortune : 213 741 $ au 31/05/2024
Postes actifs de Albert Seymour
Sociétés | Poste | Début | Fin |
---|---|---|---|
Ensoma, Inc.
![]() Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Directeur/Membre du Conseil | - | - |
Seamless Therapeutics
![]() Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Directeur Général | 23/04/2024 | - |
President | 23/04/2024 | - | |
Directeur Technique/Scientifique/R&D | - | 23/04/2024 |
Historique de carrière de Albert Seymour
Anciens postes connus de Albert Seymour
Sociétés | Poste | Début | Fin |
---|---|---|---|
Q32 BIO INC. | Directeur/Membre du Conseil | 06/09/2022 | 17/11/2023 |
Directeur Général | 06/09/2022 | 17/11/2023 | |
Directeur Technique/Scientifique/R&D | 01/04/2016 | 06/09/2022 | |
President | 21/04/2022 | 17/11/2023 | |
Shire Pharmaceuticals, Inc.
![]() Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/01/2011 | 01/03/2016 |
Formation de Albert Seymour
University of Pittsburgh | Doctorate Degree |
The Johns Hopkins University | Graduate Degree |
University of Delaware | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectorielle
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Shire Pharmaceuticals, Inc.
![]() Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Homology Medicines, Inc.
![]() Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Ensoma, Inc.
![]() Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Seamless Therapeutics
![]() Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Technology Services |
- Bourse
- Insiders
- Albert Seymour
- Expérience